ZA9610183B - Process for the diagnosis and treatment of squamous cell carcinomas - Google Patents

Process for the diagnosis and treatment of squamous cell carcinomas

Info

Publication number
ZA9610183B
ZA9610183B ZA9610183A ZA9610183A ZA9610183B ZA 9610183 B ZA9610183 B ZA 9610183B ZA 9610183 A ZA9610183 A ZA 9610183A ZA 9610183 A ZA9610183 A ZA 9610183A ZA 9610183 B ZA9610183 B ZA 9610183B
Authority
ZA
South Africa
Prior art keywords
diagnosis
treatment
squamous cell
cell carcinomas
carcinomas
Prior art date
Application number
ZA9610183A
Inventor
Karl-Heinz Heider
Guenther Adolf
Elinborg Ostermann
Erik Patzelt
Marlies Sproll
Original Assignee
Karlsruhe Forschzent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karlsruhe Forschzent filed Critical Karlsruhe Forschzent
Publication of ZA9610183B publication Critical patent/ZA9610183B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
ZA9610183A 1995-12-06 1996-12-04 Process for the diagnosis and treatment of squamous cell carcinomas ZA9610183B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19545472A DE19545472A1 (en) 1995-12-06 1995-12-06 Diagnosis of squamous epithelial cell carcinoma

Publications (1)

Publication Number Publication Date
ZA9610183B true ZA9610183B (en) 1997-06-06

Family

ID=7779323

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9610183A ZA9610183B (en) 1995-12-06 1996-12-04 Process for the diagnosis and treatment of squamous cell carcinomas

Country Status (5)

Country Link
DE (1) DE19545472A1 (en)
IL (1) IL124714A0 (en)
RU (1) RU2193779C2 (en)
UA (1) UA61065C2 (en)
ZA (1) ZA9610183B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1417974A1 (en) * 2002-11-08 2004-05-12 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
JP5763105B2 (en) * 2010-02-04 2015-08-12 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Monoclonal antibody against CD44 used for the treatment of squamous cell carcinoma of the head and neck

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0651822B1 (en) * 1992-07-21 1996-04-17 Isis Innovation Limited Diagnostic method
CA2149635A1 (en) * 1992-11-20 1994-06-09 David Tarin Peptide corresponding to cd44 exon 6, antibodies specific for said peptide and use of these antibodies for diagnosis of tumors
WO1995000658A1 (en) * 1993-06-18 1995-01-05 Sirpa Jalkanen COMPOSITIONS AND DIAGNOSTIC METHODS USING MONOCLONAL ANTIBODIES AGAINST CD44v6
EP0767380A1 (en) * 1993-06-22 1997-04-09 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Method for the diagnosis and analysis of cervix carcinoma

Also Published As

Publication number Publication date
UA61065C2 (en) 2003-11-17
DE19545472A1 (en) 1997-06-12
IL124714A0 (en) 1999-01-26
RU2193779C2 (en) 2002-11-27

Similar Documents

Publication Publication Date Title
AU4958096A (en) Process for the treatment of gases
PL324284A1 (en) Methods of treating diabetes
AU5750796A (en) System for the treatment of insomnia
ZA962344B (en) Process and crystal forms of 2-methyl-thieno-benzodiazepine.
AU7379896A (en) Method and apparatus for improving the function of sensory cells
AU3552195A (en) Improved patient-transport and treatment apparatus
GB9624256D0 (en) Watere treatment process and system
HK1000581A1 (en) Battery electrode substrate and process for producing the same
AUPM761094A0 (en) Treatment of hides
GB9519033D0 (en) Treatment
EP0761718A3 (en) Process for the preparation of poly-o-hydroxyamides and poly-o-mercaptoamides
AU1587595A (en) Process for the treatment of contaminated material
AU4090289A (en) Method for the treatment of wool
AU7310896A (en) Use of nitroflavonoids for the treatment of anxiety
HK1011462A1 (en) Electrode substrate for battery and process for preparing the same
AU8048494A (en) Fluid treatment process
AU1587495A (en) Process for the treatment of contaminated land
EP0761721A3 (en) Process for the preparation of poly-o-hydroxyamides and poly-o-mercaptoamides
ZA965191B (en) Cell treatment
AUPM959994A0 (en) Water treatment process
GB9511214D0 (en) Surface treatment
ZA962021B (en) Process for the treatment of sealable film surface
EP0761719A3 (en) Process for the preparation of poly-o-hydroxyamides and poly-o-mercaptoamides
ZA9610183B (en) Process for the diagnosis and treatment of squamous cell carcinomas
AU6829696A (en) Treatment of solutions